contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-to-publish-financial-statements-release-for-financial-year-july-2022-june-2023-on-28-september-2023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

AI also says that there are currently over 7,000 unemployed people in South Karelia. This is quite a decent income for NG again, if all these individuals receive this service, say, within the next year, and one sample costs, for example, a hundred. A tidy turnover quickly accumulates from these ‘small tasks’, and NG proved a long time ago that their labs do deliver as long as samples are brought in.

And yet, it is much cheaper to pay for all those blood tests, have a comprehensive risk assessment completed, and start treatment based on that. Treating a sick person always costs so much more than prevention that the funds will be found as long as research can demonstrate (just as has been done here) that by paying for all of these, savings are made in the total cost. See the bottom row of the graph and compare it to the two rows circled in red.

Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction.  European Heart Journal (2025), December 15 https://doi.org/10.1093/eurheartj/ehaf947 It is also worth reading the publication itself. In this, Nightingale’s blood value measurement was indeed utilized, but this study does not use Nightingale’s risk models—meaning, perhaps the company’s blood analysis was used, but not its risk analysis. An independent research group has developed its own statistical models here to predict the risk of cardiovascular events. These are not in use at NG. In this study, 11 common clinical chemistry laboratory tests (e.g., HbA1c, Vitamin D, CRP) were also clearly superior in risk classification compared to NMR-measured metabolites. The result was a round win for traditional clinical chemistry: 11.6% of those who suffered a cardiac event were better classified vs. 8.9% with comprehensive metabolomic measurements. NG’s own risk model would certainly be much worse because it only measures about 36 blood values, whereas in this study model, there were 106. If the matter were framed in the same way NG headlines its press releases: “Significant study: a standard blood test helps prevent more heart attacks and strokes compared to the current Nightingale Health blood analysis”  Of course, one can always argue, as in this article, that combining all of these leads to the best result, etc., but if there is money for only one of these, Nightingale’s measurement and risk model are not worth choosing based on this. The experimental nature of this article is also quite far from real life: people would need to have a SCORE2 risk test (measuring blood pressure, etc.), clinical chemistry labs, NG’s metabolic panel, and even a genetic panel to decide “best” whether to start cholesterol medication  The cost would likely be staggering, which was not addressed here at all. But just if NG’s test costs €200, then based on the information in this article, the price for one prevented heart attack would be €217,000 (when 100,000 people are screened with the study’s NMR risk model + SCORE2). Here, the effect of cholesterol medications is also assumed very optimistically, so the price in real life would be significantly higher.

I wonder if the analyst knows whether the implementation experiences in Etelä-Savo served as a positive springboard for North Karelia? (Enthusiasm based on results would, of course, be years away.)

a new North Karelia project?.. In my opinion, a good example of what NH’s method can aim for in Finland and similarly elsewhere in aging Western countries. The number of people needing care is increasing, the number of funders is decreasing, and treatments also seem to be getting more expensive. Often, the most cost-effective approach is preventative care, and I believe that more precise prescription of statins is just the tip of the iceberg. NH’s analytics improve the risk indicator and also provide precise information for improving different areas, in my view, more credibly than anything used before. It then remains to be seen how this translates into lifestyles, which I believe can have the greatest impact. Looking at the state of the national economy, where 7-9% (copilot) of the state budget is spent on “preventable” diseases/ailments, it would be almost mandatory to shift the focus from medical care to health maintenance. This is, of course, difficult when the citizen themselves is responsible, but all aids are welcome.

It’s quite small-scale for now, but I suppose that’s how it is when a new concept is introduced to a conservative industry—the first steps are small.

Press Release New wellbeing services county joins – North Karelia adopts disease risk identification as part of public healthcare 18.12.2025 at 15:00 Nightingale Health Nightingale Health Plc | Press Release | 18.12.2025 at 15:00:00 EET The North Karelia wellbeing services county pilots Nightingale Health’s blood analysis as part of health checks for the unemployed – the goal is a cost-effective and impactful preventive healthcare operating model. Nightingale Health’s goal is to develop a cost-effective and impactful healthcare operating model that helps target healthcare resources and strengthens preventive healthcare in the wellbeing services county. This pilot will accumulate valuable information on morbidity, changes in risks, and the effectiveness of interventions, supporting evidence-based decision-making. The health check for the unemployed is a statutory service intended to map and promote the health and wellbeing of an unemployed person and to support their work and functional capacity. The service is based on the Health Care Act and is aimed at individuals who are not covered by occupational or student healthcare. Nightingale Health’s technology is already in extensive use in the private sector, in the occupational health services of Terveystalo, Finland’s largest private healthcare provider. Nightingale Health announced earlier this autumn the expansion of its use in the private sector to all customer segments. Now, the use of the technology is expanding in public healthcare to a second wellbeing services county, the first being the previously announced South Savo wellbeing services county, further accelerating equitable and impactful preventive healthcare in Finland. “Nightingale’s technology offers a unique and cost-effective opportunity for identifying disease risks and targeting preventive measures at the population level. It is great that the North Karelia wellbeing services county is also joining to build an example of how preventive healthcare can be implemented extensively and impactfully as part of primary healthcare,” says Teemu Suna, CEO and Founder of Nightingale Health. “We need smarter ways to keep people healthy. With this pilot, as part of developing the health check process for the unemployed, we want to try earlier identification of disease risks and provide both healthcare professionals and individuals with clear and practical information about an individual’s health. Starting with health checks for the unemployed is logical – they are already part of statutory care and provide a natural platform for developing preventive services,” says Susanna Wilén, Director of Health and Wellbeing Services at the North Karelia wellbeing services county. The project will start immediately with a preparatory project, and the goal is to begin offering the Nightingale Health test as part of health checks for the unemployed in the first half of 2026. For more information, please contact: Teemu Suna, CEO

Nightingale Health

Press release, 14 September 2023 at 2:30 p.m. (EEST) Nightingale Health Plc will publish its financial statements release for the financial year July 2022-June 2023 on 28 September 2023 at around...

Press release, 14 September 2023 at 2:30 p.m. (EEST)&nbsp;Nightingale Health Plc will publish its financial statements release for the financial year July 2022-June 2023 on 28 September 2023 at around 9 a.m. EEST. Materials will be made available soon after publication at www.nightingalehealth.com/investors.&nbsp;&nbsp;Nightingale Health will arrange a live webcast for investors and media in English on 28 September 2023 at 2 p.m. EEST. You can watch the webcast online at <a href="https://nightingalehealth.videosync.fi/2022-2023-results.">https://nightingalehealth.videosync.fi/2022-2023-results.&nbsp;</a>The strategy update announced on 11 September 2023 will also be presented during the webcast.&nbsp;A presentation will held by CEO Teemu Suna and CFO Tuukka Paavola. A recording of the event will be available later the same day at www.nightingalehealth.com/investors.&nbsp;For further information, please contact:&nbsp;Nightingale Health Investor Relations&nbsp; ir@nightingalehealth.comAbout Nightingale Health&nbsp;Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.&nbsp;Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: <a href="https://nightingalehealth.com">https://nightingalehealth.com</a>